COMPASS Pathways' COMP360 Phase 3 (TRD) will not receive an FDA advisory committee scheduling notice before 2026-10-15.

Before the FDA approves a new drug, it often convenes an advisory committee — a panel of outside experts who publicly review the evidence and vote on whether the drug seems safe and effective. Compass Pathways hasn't yet submitted a full application for COMP360 as a treatment for hard-to-treat depression, and the FDA has many competing priorities. So no scheduling notice for such a panel meeting is expected before October 15, 2026.

No filing signal today; FDA bandwidth consumed elsewhere. Rigorous review timelines don't compress on political enthusiasm alone.